ReviewTopics in current chemistry (Cham)2025
Progress in the Synthesis and Application of Phycocyanin-Based Nanoparticles.
Review in Topics in current chemistry (Cham), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phycocyanin, a phycobiliprotein, is a known antimicrobial and anticancer compound, and among nanoparticle formulations, its use has garnered significant attention regarding the treatment of cancers and bacterial and parasitic diseases. Phycocyanin has been deployed in a wide range of nanoparticles amid polymer (chitosan, polylactic acid-co-glycolic acid, polypyrrole, and hydrogel nanoparticles) and non-polymer (liposomes, phytosomes, micelles, microspheres, manganese dioxide, and black phosphorus quantum dots) entities. Phycocyanin-based nanoparticles were previously limited to utilizing their anticancer and antimicrobial effects, but recent studies have revealed that they target a variety of cellular and molecular processes, such as apoptosis, cell cycle arrest, angiogenesis, and metastasis. In addition, phycocyanin-based nanoparticles have demonstrated efficacy in inhibiting the growth of various parasites and bacteria, including Cryptosporidium, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Serratia marcescens, and Bacillus cereus. Herein, various forms of phycocyanin-based nanoparticles are evaluated, emphasizing the cellular and molecular pathways involved in cancer and microbial therapy.
Indexed as
Identifiers
41400876What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.